Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy
Seeking Alpha,
Summary Recent dip in CAPR's stock price following update on regulatory pathway for CAP-1002 and cash raise represents a buying…